medigraphic.com
ISSN 0035-0052 (Print)

2018, Number 6

<< Back Next >>

Rev Mex Pediatr 2018; 85 (6)

Association of serum levels of intact parathormone with markers of metabolic bone disease in premature infants

Nieto-Flores AG, Pinacho-Velázquez JL, Iglesias-Leboreiro J, Bernárdez-Zapata I, Ramos-Méndez AM, Pérez-Lara A, Acuña-Tovar M

Language: Spanish
References: 17
Page: 201-206
PDF size: 248.58 Kb.


ABSTRACT

Introduction: Bone metabolic disease (BMD) is common in preterm infants. Recent studies suggest that serum intact parathyroid hormone (iPTH) could be a good marker for this disease. The aim of this study is to determine the association of serum levels of iPTH with BMD markers in preterm infants. Material and methods: Observational and longitudinal study performed in a neonatal intensive care unit of a private hospital in Mexico City. Bone resorption markers (calcium, phosphorus, magnesium, alkaline phosphatase, iPTH) and x-rays of long bones were measured at 24 h and at two weeks of life. Logistic regression was performed to determine factors associated with elevation of iPTH. Results: We included 40 premature (40% male / 60% female). On day one and 14 of extra-uterine life, elevation of iPTH was detected in 50% and 43.8%, and hyperphosphatemia in 67.5% and 62.5%, respectively. Alkaline phosphatase levels were elevated at 14 days compared to the first day (p ‹ 0.05). IPTH levels at 14 days were inversely correlated with weight and height at birth, while iPTH levels on the first day of life were correlated inversely with calcium and alkaline phosphatase two weeks. Factors associated with elevation of iPTH were birth weight, corrected calcium, and phosphemia. Conclusions: In premature seems appropriate measure iPTH, along with other markers of bone resorption, for the presence of BMD.


REFERENCES

  1. Rustico SE, Calabria AC, Garber SJ. Metabolic bone disease of prematurity. J Clin Transl Endocrinol. 2014; 1(3): 85-91.

  2. Vachharajani AJ. Metabolic bone disease of prematurity. Neoreviews. 2010; 10: 402-411. doi: 10.1542/neo.10-8-e402.

  3. Lothe A, Sinn J, Stone M. Metabolic bone disease of prematurity and secondary hyperparathyroidism. J Paediatr Child Health. 2011; 47(8): 550-553. doi: 10.1111/j.1440-1754.2011.02019.x.

  4. Koike T, Iwamoto M, Shimazu A, Nakashima K, Suzuki F, Kato Y. Potent mitogenic effects of parathyroid hormone (PTH) on embryonic chick and rabbit chondrocytes. Differential effects of age on growth, proteoglycan, and cyclic AMP responses of chondrocytes to PTH. J Clin Invest. 1990; 85(3): 626-631. doi: 10.1172/JCI114484.

  5. Backström MC, Kuusela AL, Mäki R. Metabolic bone disease of prematurity. Ann Med. 1996; 28(4): 275-282.

  6. Rehman MU, Narchi H. Metabolic bone disease in the preterm infant: Current state and future directions. World J Methodol. 2015; 5(3): 115-121.

  7. Kelly A, Kovatch KJ, Garber SJ. Metabolic bone disease screening practices among U.S. neonatologists. Clin Pediatr (Phila). 2014; 53(11): 1077-1083.

  8. Moreira A, February M, Geary C. Parathyroid hormone levels in neonates with suspected osteopenia. J Paediatr Child Health. 2013; 49(1): E12-E16.

  9. Rustico SE, Kelly A, Monk HM, Calabria AC. Calcitriol treatment in metabolic bone disease of prematurity with elevated parathyroid hormone: a preliminary study. J Clin Transl Endocrinol. 2014; 2(1): 14-20.

  10. Dowa Y, Kawai M, Kanazawa H, Iwanaga K, Matsukura T, Heike T. Screening for secondary hyperparathyroidism in preterm infants. Pediatr Int. 2016; 58(10): 988-992.

  11. Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium and lactation. Endocr Rev. 1997; 18: 832-872.

  12. Saggese G, Baroncelli GI, Bertelloni S, Bottone E. Intact PTH levels in healthy term neonates (HTN) and in early neonatal hypocalcemia (ENH). Pediatric Research. 1988; 23: 138.

  13. Bozzetti V, Tagliabue P. Metabolic Bone Disease in preterm newborn: an update on nutritional issues. Ital J Pediatr. 2009; 35(1): 20.

  14. Brooke OG, Lucas A. Metabolic bone disease in preterm infants. Arch Dis Child. 1985; 60(7): 682-685.

  15. Lucas A, Brooke OG, Baker BA, Bishop N, Morley R. High alkaline phosphatase activity and growth in preterm neonates. Arch Dis Child. 1989; 64(7): 902-909.

  16. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7): 1911-1930.

  17. Abrams SA; Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics. 2013; 131(5): e1676-e1683.




2020     |     www.medigraphic.com